Experienced in Aplasia Cutis Congenita

Dr. Anna Bruckner

Pediatrics
Children's Hospital Colorado
13123 E 16th Ave, 
Aurora, CO 
Experienced in Aplasia Cutis Congenita
Children's Hospital Colorado
13123 E 16th Ave, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anna Bruckner is a Pediatrics provider in Aurora, Colorado. Dr. Bruckner is rated as an Experienced provider by MediFind in the treatment of Aplasia Cutis Congenita. Her top areas of expertise are Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa, and Dowling-Meara Epidermolysis Bullosa Simplex.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Aplasia Cutis Congenita.

Specialties
Pediatrics
Licenses
Dermatology in CO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 14 Less Insurance Carriers -

Locations

Children's Hospital Colorado
13123 E 16th Ave, Aurora, CO 80045
Other Locations
Children's Hospital Colorado
1811 Plaza Dr, Highlands Ranch, CO 80129

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Enrollment Status: Terminated
Publish Date: December 01, 2025
Intervention Type: Drug
Study Drug: Sirolimus
Study Phase: Phase 2
Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma
Use of Otoscope as a Non-invasive Tool for Diagnosis of Pilomatricoma
Enrollment Status: Completed
Publish Date: December 27, 2024
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
A Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa
Enrollment Status: Active_not_recruiting
Publish Date: April 01, 2024
Intervention Type: Biological
Study Drug: FCX-007 (Dabocemagene Autoficel)
Study Phase: Phase 3
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Drug
Study Drug: Oleogel-S10
Study Phase: Phase 3
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 2 Open-Label Study of PTR-01 in Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Drug: PTR-01
Study Phase: Phase 2
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
A First in Human, Double-blind, Randomized, Intra-subject Placebo-controlled, Multiple Dose Study of QR-313 Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With DDEB or RDEB Due to Mutation(s) in Exon 73 of the COL7A1 Gene
Enrollment Status: Terminated
Publish Date: August 25, 2021
Intervention Type: Drug
Study Drug: QR-313
Study Phase: Phase 1/Phase 2
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Enrollment Status: Completed
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

77 Total Publications

Methodological Concerns in the EASE Study of Oleogel-S10 for Epidermolysis Bullosa: reply from authors.
Methodological Concerns in the EASE Study of Oleogel-S10 for Epidermolysis Bullosa: reply from authors.
Journal: The British journal of dermatology
Published: September 10, 2025
Similar Doctors
Experienced in Aplasia Cutis Congenita
Dr. Rebecca L. Harlow
Pediatrics
Experienced in Aplasia Cutis Congenita
Dr. Rebecca L. Harlow
Pediatrics

Optum Care Of Colorado Springs, LLC

8890 N Union Blvd, Ste 220 - Pediatrics, 
Colorado Springs, CO 
 (54.1 miles away)
719-574-9191
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Harlow is a Pediatrics provider in Colorado Springs, Colorado. Dr. Harlow is rated as an Experienced provider by MediFind in the treatment of Aplasia Cutis Congenita. Her top areas of expertise are Delayed Growth, Aplasia Cutis Congenita, Croup, and Sunken Fontanelles. Dr. Harlow is currently accepting new patients.

Experienced in Aplasia Cutis Congenita
Dr. Brian T. Gablehouse
Pediatrics
Experienced in Aplasia Cutis Congenita
Dr. Brian T. Gablehouse
Pediatrics

Peak Pediatrics

2900 East 136th Avenue, Suite 201, 
Thornton, CO 
 (14.4 miles away)
303-996-6005
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Gablehouse is a Pediatrics provider in Thornton, Colorado. Dr. Gablehouse is rated as an Advanced provider by MediFind in the treatment of Aplasia Cutis Congenita. His top areas of expertise are Obesity in Children, Delayed Growth, Croup, and Jaundice. Dr. Gablehouse is currently accepting new patients.

Experienced in Aplasia Cutis Congenita
Dr. Elizabeth G. Sweeney
Pediatrics
Experienced in Aplasia Cutis Congenita
Dr. Elizabeth G. Sweeney
Pediatrics

Children's Medical Center

1818 North Ogden Street, Suite 300, 
Denver, CO 
 (7.3 miles away)
303-830-7337
Experience:
18+ years
Languages Spoken:
English, French, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Elizabeth Sweeney is a Pediatrics provider in Denver, Colorado. Dr. Sweeney has been practicing medicine for over 18 years and is rated as an Experienced provider by MediFind in the treatment of Aplasia Cutis Congenita. Her top areas of expertise are Obesity in Children, Croup, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), and Developmental Dysphasia Familial. Dr. Sweeney is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bruckner's expertise for a condition
ConditionClose
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile